Biomarker predicts survival in recurrent/metastatic cutaneous SCC

  • Maly CJ & al.
  • J Am Acad Dermatol
  • 19 Aug 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low expression of inositol polyphosphate-5-phosphatase (INPP5A) is associated with reduced survival in patients with recurrent/metastatic cutaneous squamous cell carcinoma (cSCC).

Why this matters

  • INPP5A represents the first biomarker for stratification of recurrent/metastatic cSCC.

Key results

  • 78.8% of primary tumors had high INPP5A expression, while 21.2% had low expression.
  • 69.2% of recurrent/metastatic disease tumors had high INPP5A expression, while 30.8% had low expression.
  • Low vs high staining expression of INPP5A in the recurrent/metastatic disease tumor was associated with reduced OS (31.0 vs 62.0 months; P=.0272).
    • INPP5A levels in the primary tumor were not significantly associated with OS (31.0 vs 57.0 months for low vs high, P=.0897).
  • A composite risk score based on INPP5A expression in the primary and recurrent/metastatic tumors was associated with OS (HR, 0.42; P=.0113 for a score of 0 vs a score ≥1).

Study design

  • 50 patients with recurrent/metastatic cSCC were analyzed for INPP5A staining and associations with survival.
  • Funding: Dermatology Foundation, NIH.

Limitations

  • Retrospective study.
  • Small patient sample size.